Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MDxHealth SA (MDXH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer. MDxHealth files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed information on its precision diagnostics business for prostate cancer and other urologic diseases, its financial condition, and material corporate events.
Form 20-F filings contain audited financial statements prepared under International Financial Reporting Standards (IFRS), along with sections on business description, risk factors, management’s discussion and analysis, and details of MDxHealth’s molecular diagnostic portfolio. For a company that derives revenue from clinical laboratory service testing and out-licensing of its DNA methylation platform and biomarkers, these annual reports are a key resource for understanding revenue composition, research and development spending, and acquisition accounting.
Form 6-K reports are used by MDxHealth to furnish press releases and interim reports, including quarterly and half-year financial results, acquisition announcements such as the Exosome Diagnostics transaction, amendments to earnout obligations related to the GPS prostate cancer business, management and board changes, and other significant updates. Some 6-K exhibits, such as interim reports, may be incorporated by reference into the company’s shelf registration statements on Form F-3, as noted in the filings.
On Stock Titan, MDXH filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries that highlight the main points in complex documents. Users can quickly scan annual 20-F reports, interim 6-Ks, and related exhibits to identify information on MDxHealth’s precision diagnostics operations, risk disclosures, financing arrangements, and acquisition-related commitments, without reading each filing in full.
MDxHealth presents an annual report highlighting continued losses, going concern uncertainty and reliance on key prostate cancer tests. As of December 31, 2025, the company had an accumulated deficit of $403.0 million, a 2025 net loss of $33.5 million and net cash outflows from operations of $2.2 million. Management expects further losses and notes that failure to raise capital could jeopardize its ability to continue as a going concern. A $100 million senior secured credit facility with OrbiMed, maturing in 2029, imposes revenue and liquidity covenants and is secured by substantially all assets. Revenue is concentrated in Confirm mdx and GPS mdx tests, which generated about 76% of 2025 revenue and depend heavily on Medicare and commercial reimbursement. The report also describes intense competition in molecular diagnostics, complex billing and reimbursement risk, extensive regulatory exposure, and the importance of MDxHealth’s patent portfolio and CLIA-certified laboratories.
MDxHealth SA director Michael Holder reports initial holdings of share options. The filing shows options to purchase 10,000 ordinary shares at an exercise price of $2.18 per share, granted on June 27, 2025. These options vest in full at the annual general shareholders' meeting held in the calendar year after the grant year and expire on June 27, 2035.
MVM Partners, LLC has filed an initial ownership report for MDxHealth SA, showing indirect holdings of 4,700,457 Ordinary Shares. These shares are held by private investment funds managed by MVM Partners. MVM states that it may be deemed a beneficial owner through its role as investment manager but disclaims beneficial ownership beyond any pecuniary interest.
MDxHealth reported strong growth for the year ended December 31, 2025, with revenue up 20% to $107.9 million and fourth-quarter revenue up 19% to $29.5 million. Growth was driven mainly by its urology-focused precision diagnostic tests, with tissue-based tests providing most of sales.
Full-year gross profit rose 26% to $69.6 million, and gross margin improved to 64.5% from 61.2%, helped by better fixed-cost absorption. Operating expenses increased 5% to $84.0 million, reflecting acquisition-related costs and higher headcount tied to the ExoDx business.
The company reduced its operating loss to $14.4 million from $24.7 million, and net loss narrowed 12% to $33.5 million. Adjusted EBITDA improved sharply to a loss of $1.1 million from a loss of $14.7 million, indicating progress toward profitability. Cash and cash equivalents were $29.0 million at year-end.
For 2026, MDxHealth guides revenue to $137–140 million, implying 27–30% growth, and aims to reach an adjusted EBITDA margin of 10% exiting 2026.
MDxHealth is registering up to $200,000,000 of ordinary shares on a shelf basis, allowing primary offerings from time to time, including a $50,000,000 at-the-market program under a sales agreement. A separate secondary prospectus covers 1,867,186 ordinary shares for resale, outside this $200,000,000 capacity.
The company is a commercial-stage precision diagnostics business focused on urologic cancers, with core tests ExoDx, Confirm mdx and GPS. It qualifies as both an emerging growth company and a foreign private issuer, using reduced U.S. reporting requirements.
Risk factors emphasize continued losses and liquidity pressure. As of December 31, 2024, MDxHealth had an accumulated deficit of $369.5 million, a 2024 net loss of $38.1 million and operating cash outflows of $18.5 million, and its financial statements are prepared on a going-concern basis. The company also has a senior secured credit facility of up to $100 million with OrbiMed and outstanding deferred acquisition obligations, including up to $10 million related to Exosome Diagnostics and up to $54.5 million tied to the GPS business, all of which may require substantial future cash or share payments.
MDxHealth reports on its acquisition of Exosome Diagnostics and an amended earnout arrangement for a prior GPS transaction. The company agreed to acquire Exosome Diagnostics, including the ExoDx prostate cancer test and CLIA lab, for up to $15 million, with about $5 million in stock at closing and four subsequent annual instalments of $2.5 million each, partly in cash and partly in cash or stock at MDxHealth’s discretion.
Audited 2025 financials for Exosome Diagnostics show sales of $27.3 million and a net loss of $86.5 million, driven largely by impairment charges. MDxHealth also amended the GPS acquisition earnout with Exact Sciences, rescheduling remaining payments to $15.0 million in 2026, $18.0 million in 2027 and $21.5 million in 2028, and issuing warrants for 3 million MDxHealth shares at an exercise price of $5.265 per share.
MDxHealth SA received an updated ownership report showing that Genomic Health, Inc., a Delaware company and wholly owned subsidiary of Exact Sciences Corporation, beneficially owns a total of 6,441,171 ordinary shares of MDxHealth. This total includes 2,441,171 ordinary shares directly owned and warrants or contractual rights to purchase an additional 4,000,000 ordinary shares.
The filing states this represents 12.0% of MDxHealth’s ordinary shares, based on 49,497,334 ordinary shares issued and outstanding as described in MDxHealth’s Form F-3 registration statement filed on December 29, 2025. Exact Sciences may be deemed to beneficially own the shares held by Genomic Health, and the reporting persons certify that the securities are not held for the purpose of changing or influencing control of MDxHealth.
MDxHealth SA reported preliminary 2025 revenue of about $109 million, with fourth quarter revenue of about $30.5 million, reflecting year-over-year growth of 21% and 23%, respectively. In the quarter, the company billed 11,201 tissue-based and 27,486 liquid-based units, while full-year volumes reached 49,180 tissue-based and 71,920 liquid-based units, with especially strong liquid-based growth. Year-end cash was $29.0 million.
For 2026, MDxHealth guides revenue to $137–140 million, implying growth of about 26–28%, and targets an adjusted EBITDA margin run rate of 10% exiting 2026. The company also amended the earnout related to its 2022 GPS acquisition from Exact Sciences, deferring payments into three installments of $15.0 million in 2026, $18.0 million in 2027, and $21.5 million in 2028, and agreed to issue warrants for 3 million shares at an exercise price of $5.265 per share.